用于靶向药物给药的磁性纳米粒子由于其显着的优点，例如与传统药物递送方法相比，具有靶向性和增强的封装能力以及改善的生物保护能力，在癌症治疗中提供了一种有前景的方法。金壳铁核纳米颗粒 (Fe3O4@Au) 通过化学工艺制造，涂有葡聚糖以封装姜黄素，并使用叶酸进行功能化以实现精确药物输送以对抗肝癌。应用动态光散射、扫描电子显微镜、透射电子显微镜、振动光谱和磁力测定法评估 Fe3O4@Au-DEX-CU-FA 化合物的合成。 Fe3O4@Au-DEX-CU-FA 的平均尺寸、zeta 电位和多分散性分别为 63.3 ± 2.33 nm、-68.3 ± 1.78 mV 和 0.041 ± 0.008。创建分子对接模型来检查 Fe3O4@Au-CU 和 BCL-XL、BAK 之间的关系，并确定潜在的结合位点。装载效率和释放曲线测试检查了药物输送系统的能力。随后利用 MTT 测定确定 Fe3O4@Au-DEX-CU-FA 对癌症 SNU-449 和健康 THLE-2 细胞系的最佳剂量和治疗效果。流式细胞术证明 Fe3O4@Au-DEX-CU-FA 有效诱导癌细胞死亡。 Fe3O4@Au-DEX-FA 在 37 °C、pH 值 7.4 和 5.4 下表现出游离姜黄素的调节释放曲线。实时 PCR 显示 BAK 表达增加，BCL-XL 表达减少。使用荷瘤裸鼠进行体内实验。与游离 CU 和对照处理相比，Fe3O4@Au-DEX-CU-FA 处理显着减小了肿胀尺寸。它还可以延长寿命、扩大脾细胞增殖、增加 IFN-γ 水平并降低 IL-4 水平。与癌症类型相比，常规细胞没有表现出细胞毒性作用，证实 Fe3O4@Au-DEX-CU-FA 保持了其有效的抗癌作用。数据表明 Fe3O4@Au-DEX-CU-FA 作为抗肿瘤治疗剂具有广阔的潜力。

Magnetic nanoparticles used for targeted drug administration present a promising approach in cancer treatment owing to its notable advantages, such as targeted and enhanced encapsulation ability and improved bio protection compared with conventional drug delivery methods. Au shell-iron core nanoparticles (Fe3O4@Au) were manufactured by a chemical process, coated with dextran to encapsulate curcumin, and functionalized for precision drug delivery using folic acid to combat liver cancer. Dynamic light scattering, scanning electron microscopy, transmission electron microscopy, vibrational spectroscopy, and magnetometry were applied to assess the synthesis of the Fe3O4@Au-DEX-CU-FA compound. The mean size, zeta potential, and polydispersity of Fe3O4@Au-DEX-CU-FA were 63.3 ± 2.33 nm, -68.3 ± 1.78 mV, and 0.041 ± 0.008, respectively. Molecular docking models were created to examine the relationship between Fe3O4@Au-CU and BCL-XL, BAK, and to identify potential binding sites. The loading efficiency and release profile tests examined the medication delivery system's ability. MTT assay was subsequently utilized to determine the optimal dosage and therapeutic efficacy of Fe3O4@Au-DEX-CU-FA on cancer SNU-449 and healthy THLE-2 cell lines. Flow cytometry demonstrated that Fe3O4@Au-DEX-CU-FA effectively induced cancer cell death. Fe3O4@Au-DEX-FA showed a regulated release profile of free curcumin at 37 °C and pH values of 7.4 and 5.4. Real-time PCR revealed increased BAK expression and decreased BCL-XL expression. Nude tumor-bearing mice were used for in vivo experiments. Fe3O4@Au-DEX-CU-FA treatment dramatically reduced the swelling size compared with free CU and control treatments. It also resulted in a longer lifespan, expanded splenocyte proliferation, increased IFN-γ levels, and decreased IL-4 levels. The regular cells showed no cytotoxic effect compared with the cancer type, confirming that Fe3O4@Au-DEX-CU-FA maintained its potent anticancer actions. The data suggests that Fe3O4@Au-DEX-CU-FA possesses a promising potential as a therapeutic agent for combating tumors.